Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2020 Filed Jun 8, 2020 23:24 UTC |
Welch David FDirector
|
Exercise / conversionCommon Stock | 2,259,102 | $0.50 | $1,129,551.00 |
DisclosureSEC source: 0001807094-20-000008 · primary_doc.xml · nonDerivative · entry 3 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 9,513,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The reported securities of the Issuer are held by LRFA, LLC, a Delaware limited liability company ("LRFA"), wholly owned and managed by the reporting person. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 19:29 UTC |
Colachis ArianGC and Corporate Secretary
|
GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001807094-20-000002 · primary_doc.xml · derivative · entry 1 Colachis Arian · CIK 0001807094 · GC and Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: The options will vest in three equal installments over a three-year period beginning March 16, 2021. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:07 UTC |
Eastwood Craig S.Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0000899243-20-005791 · doc4.xml · derivative · entry 1 Eastwood Craig S. · CIK 0001701834 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-02-21 F1 · derivative.exercise_date: The options will fully vest on February 21, 2021. Read SEC document |
| February 21, 2020 Filed Jun 8, 2020 23:24 UTC |
Welch David FDirector
|
Exercise / conversionWarrant (Right to BuyO · Derivative | 1,819,672 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001807094-20-000008 · primary_doc.xml · derivative · entry 9 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 1,819,672 shares Expires 2020-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The reported securities of the Issuer are held by LRFA, LLC, a Delaware limited liability company ("LRFA"), wholly owned and managed by the reporting person. Read SEC document |
| February 21, 2020 Filed Jun 8, 2020 23:24 UTC |
Welch David FDirector
|
GrantWarrant (Right to Buy) · Derivative | 819,672 | Not disclosed Strike: $0.18 | Not disclosed |
DisclosureSEC source: 0001807094-20-000008 · primary_doc.xml · derivative · entry 8 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 819,672 Underlying: Common Stock · 819,672 shares Expires 2020-02-25 F3 · price: On February 20, 2020, as an inducement to exercise, the Issuer and LRFA agreed to amend two warrants held by LRFA (the "Warrants") to purchase a total of 1,819,672 shares of the Issuer's stock, par value $0.001 per share ("Common Stock"), pursuant to which the exercise price of the Warrants was reduced to 60% of the original exercise price. In connection with the amendment, the Issuer issued to LRFA an additional 181,967 shares of Common Stock. F1 · ownership.nature: The reported securities of the Issuer are held by LRFA, LLC, a Delaware limited liability company ("LRFA"), wholly owned and managed by the reporting person. Read SEC document |
| February 21, 2020 Filed Jun 8, 2020 23:24 UTC |
Welch David FDirector
|
Disposition to issuerWarrant (Right to Buy) · Derivative | 819,672 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001807094-20-000008 · primary_doc.xml · derivative · entry 7 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 819,672 shares Expires 2024-12-23 F3 · price: On February 20, 2020, as an inducement to exercise, the Issuer and LRFA agreed to amend two warrants held by LRFA (the "Warrants") to purchase a total of 1,819,672 shares of the Issuer's stock, par value $0.001 per share ("Common Stock"), pursuant to which the exercise price of the Warrants was reduced to 60% of the original exercise price. In connection with the amendment, the Issuer issued to LRFA an additional 181,967 shares of Common Stock. F1 · ownership.nature: The reported securities of the Issuer are held by LRFA, LLC, a Delaware limited liability company ("LRFA"), wholly owned and managed by the reporting person. Read SEC document |
| February 21, 2020 Filed Jun 8, 2020 23:24 UTC |
Welch David FDirector
|
GrantWarrant (Right to Buy) · Derivative | 1,000,000 | Not disclosed Strike: $0.18 | Not disclosed |
DisclosureSEC source: 0001807094-20-000008 · primary_doc.xml · derivative · entry 6 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2020-02-25 F3 · price: On February 20, 2020, as an inducement to exercise, the Issuer and LRFA agreed to amend two warrants held by LRFA (the "Warrants") to purchase a total of 1,819,672 shares of the Issuer's stock, par value $0.001 per share ("Common Stock"), pursuant to which the exercise price of the Warrants was reduced to 60% of the original exercise price. In connection with the amendment, the Issuer issued to LRFA an additional 181,967 shares of Common Stock. F1 · ownership.nature: The reported securities of the Issuer are held by LRFA, LLC, a Delaware limited liability company ("LRFA"), wholly owned and managed by the reporting person. Read SEC document |
| February 21, 2020 Filed Jun 8, 2020 23:24 UTC |
Welch David FDirector
|
Disposition to issuerWarrant (Right to Buy) · Derivative | 1,000,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001807094-20-000008 · primary_doc.xml · derivative · entry 5 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2024-09-30 F3 · price: On February 20, 2020, as an inducement to exercise, the Issuer and LRFA agreed to amend two warrants held by LRFA (the "Warrants") to purchase a total of 1,819,672 shares of the Issuer's stock, par value $0.001 per share ("Common Stock"), pursuant to which the exercise price of the Warrants was reduced to 60% of the original exercise price. In connection with the amendment, the Issuer issued to LRFA an additional 181,967 shares of Common Stock. F1 · ownership.nature: The reported securities of the Issuer are held by LRFA, LLC, a Delaware limited liability company ("LRFA"), wholly owned and managed by the reporting person. Read SEC document |
| February 21, 2020 Filed Jun 8, 2020 23:24 UTC |
Welch David FDirector
|
GrantCommon Stock | 181,967 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001807094-20-000008 · primary_doc.xml · nonDerivative · entry 2 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 7,254,315 F3 · price: On February 20, 2020, as an inducement to exercise, the Issuer and LRFA agreed to amend two warrants held by LRFA (the "Warrants") to purchase a total of 1,819,672 shares of the Issuer's stock, par value $0.001 per share ("Common Stock"), pursuant to which the exercise price of the Warrants was reduced to 60% of the original exercise price. In connection with the amendment, the Issuer issued to LRFA an additional 181,967 shares of Common Stock. F1 · ownership.nature: The reported securities of the Issuer are held by LRFA, LLC, a Delaware limited liability company ("LRFA"), wholly owned and managed by the reporting person. Read SEC document |
| February 21, 2020 Filed Jun 8, 2020 23:24 UTC |
Welch David FDirector
|
Exercise / conversionCommon Stock | 1,819,672 | $0.18 | $327,540.96 |
DisclosureSEC source: 0001807094-20-000008 · primary_doc.xml · nonDerivative · entry 1 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 7,072,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The reported securities of the Issuer are held by LRFA, LLC, a Delaware limited liability company ("LRFA"), wholly owned and managed by the reporting person. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 02:16 UTC |
Welch David FDirector
|
PurchaseWarrants · Derivative | 500,000 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0001754249-20-000001 · primary_doc.xml · derivative · entry 2 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2025-01-31 F3 · price: The reporting person purchased units, each consisting of 1 share of preferred stock and warrants to purchase 500 shares of common stock, at a purchase price of $1,000 for each unit. F1 · ownership.nature: The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA"). David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 02:16 UTC |
Welch David FDirector
|
PurchaseSeries D Convertible Preferred Stock · Derivative | 1,000 | $1,000.00 Strike: $0.80 | $1,000,000.00 |
DisclosureSEC source: 0001754249-20-000001 · primary_doc.xml · derivative · entry 1 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,000 Underlying: Common Stock · 1,250,000 shares Expires not disclosed F2 · derivative.expiration_date: The preferred stock has no expiration date. F1 · ownership.nature: The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA"). David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein. Read SEC document |
| January 18, 2020 Filed Jan 23, 2020 02:36 UTC |
TIMMINS ALAN PDirector
|
GrantStock Option (right to buy) · Derivative | 36,986 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001234898-20-000004 · primary_doc.xml · derivative · entry 1 TIMMINS ALAN P · CIK 0001234898 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,986 Underlying: Common Stock · 36,986 shares Expires 2030-01-18 F1 · derivative.exercise_date: The option will vest commencing on March 1, 2020 with respect to 11,986 shares and on June 1, 2020 with respect to 25,000 shares. Read SEC document |
| January 06, 2020 Filed Jan 9, 2020 01:31 UTC |
Fleming MauraSee Remarks
|
GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0000899243-20-000852 · doc4.xml · derivative · entry 1 Fleming Maura · CIK 0001798921 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-01-06 F1 · derivative.exercise_date: The options will vest in three equal annual installments over a three-year period, with the first installment vesting on January 6, 2021. Read SEC document |
| December 24, 2019 Filed Dec 28, 2019 01:05 UTC |
Pourhassan NaderDirector · President & CEO
|
Tax withholdingCommon Stock | 70,055 | $0.64 | $44,835.20 |
DisclosureSEC source: 0000899243-19-030134 · doc4.xml · nonDerivative · entry 2 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,417 Read SEC document |
| December 24, 2019 Filed Dec 28, 2019 01:05 UTC |
Pourhassan NaderDirector · President & CEO
|
GrantCommon Stock | 225,983 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-030134 · doc4.xml · nonDerivative · entry 1 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,472 F1 · price: The reported securities were granted in respect of an annual performance award for the fiscal year ended May 31, 2018, which had been previously approved but not yet issued. Read SEC document |
| December 24, 2019 Filed Dec 28, 2019 01:00 UTC |
Mulholland Michael D.SVP-Finance
|
Tax withholdingCommon Stock | 56,942 | $0.64 | $36,442.88 |
DisclosureSEC source: 0000899243-19-030131 · doc4.xml · nonDerivative · entry 2 Mulholland Michael D. · CIK 0001257911 · SVP-Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,081 Read SEC document |
| December 24, 2019 Filed Dec 28, 2019 01:00 UTC |
Mulholland Michael D.SVP-Finance
|
GrantCommon Stock | 153,897 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-030131 · doc4.xml · nonDerivative · entry 1 Mulholland Michael D. · CIK 0001257911 · SVP-Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,023 F1 · price: The reported securities were granted in respect of an annual performance award for the fiscal year ended May 31, 2018, which had been previously approved but not yet issued. Read SEC document |
| December 23, 2019 Filed Dec 28, 2019 02:34 UTC |
Welch David FDirector
|
GrantWarrants (right to buy) · Derivative | 819,672 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0000899243-19-030141 · doc4.xml · derivative · entry 3 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 819,672 Underlying: Common Stock · 819,672 shares Expires 2024-12-23 F3 · price: The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.305 per share of common stock and related warrants. F1 · ownership.nature: The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA"). David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein. Read SEC document |
| December 23, 2019 Filed Dec 28, 2019 02:34 UTC |
Welch David FDirector
|
GrantCommon Stock | 1,639,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-030141 · doc4.xml · nonDerivative · entry 1 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,252,676 F3 · price: The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.305 per share of common stock and related warrants. F1 · ownership.nature: The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA"). David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein. Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:11 UTC |
Mulholland Michael D.See Remarks
|
GrantStock Option (right to buy) · Derivative | 700,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-030008 · doc4.xml · derivative · entry 1 Mulholland Michael D. · CIK 0001257911 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: One-half of the options vest immediately upon grant and one-half of the options will vest upon the achievement of certain additional strategic milestones specified in the award agreement. Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:17 UTC |
Pourhassan NaderDirector · President & CEO
|
GrantWarrant (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-030010 · doc4.xml · derivative · entry 2 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: The warrant vests upon the achievement of certain additional strategic milestones. Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:17 UTC |
Pourhassan NaderDirector · President & CEO
|
GrantStock Option (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-030010 · doc4.xml · derivative · entry 1 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2029-12-19 Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:08 UTC |
Ray Nitya G.See Remarks
|
GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-030004 · doc4.xml · derivative · entry 1 Ray Nitya G. · CIK 0001709522 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: 200,000 options vest immediately upon grant and 400,000 options will vest upon the achievement of certain additional strategic milestones specified in the award agreement. Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:06 UTC |
Naydenov Jordan GDirector
|
GrantStock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-030000 · doc4.xml · derivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2029-12-19 Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:08 UTC |
Klump Michael ADirector
|
GrantStock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-030003 · doc4.xml · derivative · entry 1 Klump Michael A · CIK 0001748882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2029-12-19 Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:04 UTC |
Welch David FDirector
|
GrantStock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-029998 · doc4.xml · derivative · entry 1 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2029-12-19 Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:02 UTC |
Kelly Scott A.Director
|
GrantStock Option (right to buy) · Derivative | 1,250,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-029995 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: 750,000 options vest immediately upon grant and 500,000 options vest upon the achievement of certain additional strategic milestones specified in the award agreement. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:32 UTC |
Naydenov Jordan GDirector
|
GrantWarrants (right to buy) · Derivative | 625,000 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0000899243-19-029421 · doc4.xml · derivative · entry 2 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,000 Underlying: Common Stock · 625,000 shares Expires 2024-12-13 F1 · price: The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.30 per share of common stock and related warrants. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:32 UTC |
Naydenov Jordan GDirector
|
GrantCommon Stock | 833,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-029421 · doc4.xml · nonDerivative · entry 1 Naydenov Jordan G · CIK 0001469618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,137,823 F1 · price: The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.30 per share of common stock and related warrants. Read SEC document |
| November 13, 2019 Filed Nov 20, 2019 17:14 UTC |
Eastwood Craig S.Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-19-027662 · doc4.xml · derivative · entry 1 Eastwood Craig S. · CIK 0001701834 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-11-13 F1 · derivative.exercise_date: The options will vest in twelve equal monthly installments over the one-year period commencing on December 13, 2019. Read SEC document |
| October 08, 2019 Filed Jan 9, 2020 01:33 UTC |
Klump Michael ADirector
|
GrantWarrant (Right to Buy) · Derivative | 500,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0000899243-20-000854 · doc4.xml · derivative · entry 3 Klump Michael A · CIK 0001748882 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2024-10-08 F2 · price: The Company recently completed a convertible promissory note exchange offer in which Argonne Trading participated, among other non-affiliated investors. Pursuant to the exchange offer, as an inducement to extend the maturity date of a certain convertible promissory note (the "Original Note") beneficially owned by Mr. Klump, the Company (i) issued a new convertible promissory note in the principal amount equal to the principal amount of the Original Note plus the accrued but unpaid interest thereon and (ii) issued a warrant to purchase shares of common stock covering fifty percent of the shares of common stock into which the principal amount of the Original Note was convertible. F1 · ownership.nature: The reported securities of CytoDyn Inc. (the "Company") are held by Argonne Trading, LLC, a Georgia limited liability company ("Argonne Trading"). Argonne Capital Group, LLC, a Georgia limited liability company ("Argonne Capital"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein Read SEC document |
| October 08, 2019 Filed Jan 9, 2020 01:33 UTC |
Klump Michael ADirector
|
GrantConvertible Promissory Note · Derivative | 537,397 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0000899243-20-000854 · doc4.xml · derivative · entry 2 Klump Michael A · CIK 0001748882 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: Not disclosed Underlying: Common Stock · 1,075,758 shares Expires 2020-04-01 F2 · price: The Company recently completed a convertible promissory note exchange offer in which Argonne Trading participated, among other non-affiliated investors. Pursuant to the exchange offer, as an inducement to extend the maturity date of a certain convertible promissory note (the "Original Note") beneficially owned by Mr. Klump, the Company (i) issued a new convertible promissory note in the principal amount equal to the principal amount of the Original Note plus the accrued but unpaid interest thereon and (ii) issued a warrant to purchase shares of common stock covering fifty percent of the shares of common stock into which the principal amount of the Original Note was convertible. F1 · ownership.nature: The reported securities of CytoDyn Inc. (the "Company") are held by Argonne Trading, LLC, a Georgia limited liability company ("Argonne Trading"). Argonne Capital Group, LLC, a Georgia limited liability company ("Argonne Capital"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein Read SEC document |
| October 08, 2019 Filed Jan 9, 2020 01:33 UTC |
Klump Michael ADirector
|
Disposition to issuerConvertible Promissory Note · Derivative | 500,000 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0000899243-20-000854 · doc4.xml · derivative · entry 1 Klump Michael A · CIK 0001748882 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: Not disclosed Underlying: Common Stock · 1,000,000 shares Expires 2019-10-08 F2 · price: The Company recently completed a convertible promissory note exchange offer in which Argonne Trading participated, among other non-affiliated investors. Pursuant to the exchange offer, as an inducement to extend the maturity date of a certain convertible promissory note (the "Original Note") beneficially owned by Mr. Klump, the Company (i) issued a new convertible promissory note in the principal amount equal to the principal amount of the Original Note plus the accrued but unpaid interest thereon and (ii) issued a warrant to purchase shares of common stock covering fifty percent of the shares of common stock into which the principal amount of the Original Note was convertible. F1 · ownership.nature: The reported securities of CytoDyn Inc. (the "Company") are held by Argonne Trading, LLC, a Georgia limited liability company ("Argonne Trading"). Argonne Capital Group, LLC, a Georgia limited liability company ("Argonne Capital"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 23:05 UTC |
Pourhassan NaderDirector · President & CEO
|
GrantStock Options (right to buy) · Derivative | 375,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-025316 · doc4.xml · derivative · entry 1 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2029-10-07 F1 · derivative.exercise_date: The options will vest in twelve equal monthly installments over the one year period commencing on November 7, 2019. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 23:10 UTC |
Welch David FDirector
|
GrantStock Options (right to buy) · Derivative | 187,500 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-025318 · doc4.xml · derivative · entry 1 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2029-10-07 F1 · derivative.exercise_date: The options will vest in four equal quarterly installments over the one year period commencing on January 7, 2020. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 23:04 UTC |
Ray Nitya G.See Remarks
|
GrantStock Options (right to buy) · Derivative | 187,500 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-025314 · doc4.xml · derivative · entry 1 Ray Nitya G. · CIK 0001709522 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2029-10-07 F1 · derivative.exercise_date: The options will vest in twelve equal monthly installments over the one year period commencing on November 7, 2019. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 23:05 UTC |
Mulholland Michael D.CFO, Treasurer and Secretary
|
GrantStock Options (right to buy) · Derivative | 187,500 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-025315 · doc4.xml · derivative · entry 1 Mulholland Michael D. · CIK 0001257911 · CFO, Treasurer and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2029-10-07 F1 · derivative.exercise_date: The options will vest in twelve equal monthly installments over the one year period commencing on November 7, 2019 Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 23:03 UTC |
Kelly Scott A.Director
|
GrantStock Options (right to buy) · Derivative | 187,500 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-025311 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2029-10-07 F1 · derivative.exercise_date: The options will vest in four equal quarterly installments over the one year period commencing on January 7, 2020. Read SEC document |
| October 07, 2019 Filed Oct 11, 2019 01:44 UTC Amendment |
Ray Nitya G.See Remarks
|
GrantStock Options (right to buy) · Derivative | 187,500 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-025494 · doc4a.xml · derivative · entry 1 Ray Nitya G. · CIK 0001709522 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2029-10-07 F1 · shares: This report is being filed to correct an inadvertent error, to report the options issued October 7, 2019 as acquired (and not disposed of) in the transaction, in Column 5. F2 · derivative.exercise_date: The options will vest in twelve equal monthly installments over the one year period commencing on November 7, 2019. Read SEC document |
| October 07, 2019 Filed Oct 11, 2019 01:44 UTC Amendment |
Mulholland Michael D.CFO, Treasurer and Secretary
|
GrantStock Options (right to buy) · Derivative | 187,500 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-025493 · doc4a.xml · derivative · entry 1 Mulholland Michael D. · CIK 0001257911 · CFO, Treasurer and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2029-10-07 F1 · shares: This report is being filed to correct an inadvertent error, to report the options issued October 7, 2019 as acquired (and not disposed of) in the transaction, in Column 5. F2 · derivative.exercise_date: The options will vest in twelve equal monthly installments over the one year period commencing on November 7, 2019 Read SEC document |
| October 07, 2019 Filed Oct 11, 2019 01:43 UTC Amendment |
Welch David FDirector
|
GrantStock Options (right to buy) · Derivative | 187,500 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-025492 · doc4a.xml · derivative · entry 1 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2029-10-07 F1 · shares: This report is being filed to correct an inadvertent error, to report the options issued October 7, 2019 as acquired (and not disposed of) in the transaction, in Column 5. F2 · derivative.exercise_date: The options will vest in four equal quarterly installments over the one year period commencing on January 7, 2020. Read SEC document |
| September 30, 2019 Filed Jan 9, 2020 01:32 UTC |
Welch David FDirector
|
GrantWarrant (Right to Buy) · Derivative | 1,000,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0000899243-20-000853 · doc4.xml · derivative · entry 3 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2024-09-30 F2 · price: The Company recently completed a convertible promissory note exchange offer in which LRFA participated, among other non-affiliated investors. Pursuant to the exchange offer, as an inducement to extend the maturity date of a certain convertible promissory note (the "Original Note") beneficially owned by Dr. Welch, the Company (i) issued a new convertible promissory note (the "Exchange Note") in the principal amount equal to the principal amount of the Original Note plus the accrued but unpaid interest thereon and (ii) issued a warrant to purchase shares of common stock covering fifty percent of the shares of common stock into which the principal amount of the Original Note was convertible. F1 · ownership.nature: The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA"). David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein. Read SEC document |
| September 30, 2019 Filed Jan 9, 2020 01:32 UTC |
Welch David FDirector
|
GrantConvertible Promissory Note · Derivative | 1,075,343 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0000899243-20-000853 · doc4.xml · derivative · entry 2 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: Not disclosed Underlying: Common Stock · 2,150,686 shares Expires 2020-04-01 F2 · price: The Company recently completed a convertible promissory note exchange offer in which LRFA participated, among other non-affiliated investors. Pursuant to the exchange offer, as an inducement to extend the maturity date of a certain convertible promissory note (the "Original Note") beneficially owned by Dr. Welch, the Company (i) issued a new convertible promissory note (the "Exchange Note") in the principal amount equal to the principal amount of the Original Note plus the accrued but unpaid interest thereon and (ii) issued a warrant to purchase shares of common stock covering fifty percent of the shares of common stock into which the principal amount of the Original Note was convertible. F1 · ownership.nature: The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA"). David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein. Read SEC document |
| September 30, 2019 Filed Jan 9, 2020 01:32 UTC |
Welch David FDirector
|
Disposition to issuerConvertible Promissory Note · Derivative | 1,000,000 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0000899243-20-000853 · doc4.xml · derivative · entry 1 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: Not disclosed Underlying: Common Stock · 2,000,000 shares Expires 2019-10-01 F2 · price: The Company recently completed a convertible promissory note exchange offer in which LRFA participated, among other non-affiliated investors. Pursuant to the exchange offer, as an inducement to extend the maturity date of a certain convertible promissory note (the "Original Note") beneficially owned by Dr. Welch, the Company (i) issued a new convertible promissory note (the "Exchange Note") in the principal amount equal to the principal amount of the Original Note plus the accrued but unpaid interest thereon and (ii) issued a warrant to purchase shares of common stock covering fifty percent of the shares of common stock into which the principal amount of the Original Note was convertible. F1 · ownership.nature: The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA"). David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 21:13 UTC |
Welch David FDirector
|
GrantStock Options (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-023649 · doc4.xml · derivative · entry 1 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-09-12 Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 21:13 UTC |
Kelly Scott A.Director
|
GrantStock Options (right to buy) · Derivative | 750,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-023648 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2029-09-12 Read SEC document |
| August 09, 2019 Filed Sep 1, 2020 17:46 UTC |
Kelly Scott A.Director · Chairman & CMO
|
GiftCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001807094-20-000015 · primary_doc.xml · nonDerivative · entry 2 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Indirect · By Custodian for daughter Disclosed balance after: 97,980 F1 · shares: This transaction involved a gift of securities by the reporting person to his daughter, who shares the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 09, 2019 Filed Sep 1, 2020 17:46 UTC |
Kelly Scott A.Director · Chairman & CMO
|
GiftCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001807094-20-000015 · primary_doc.xml · nonDerivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director · Chairman & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,491,052 F1 · shares: This transaction involved a gift of securities by the reporting person to his daughter, who shares the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 21:30 UTC |
Welch David FDirector
|
Exercise / conversionWarrant (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-19-020923 · doc4.xml · derivative · entry 5 Welch David F · CIK 0001399122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2023-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA"). David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.